Lexeo Therapeutics: HC Wainwright Maintains Buy Rating, Lowers PT to $9 from $15.

Lexeo Therapeutics: HC Wainwright Maintains Buy Rating, Lowers PT to $9 from $15.

Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company specializing in cardiovascular diseases, has seen its stock receive a positive yet adjusted rating from HC Wainwright. The investment firm maintains a "Buy" rating for Lexeo but has lowered its price target from $15 to $9 [1].

The adjustment in the price target comes amidst significant advancements in Lexeo's clinical pipeline. The company recently reported receiving Breakthrough Therapy designation for its gene therapy candidate, LX2006, for Friedreich ataxia, based on interim data from Phase I/II trials demonstrating clinically meaningful improvements in cardiac and neurologic measures [1]. Additionally, Lexeo has been selected to participate in the FDA Chemistry, Manufacturing, and Controls (CMC) Development Readiness Pilot (CDRP) program, which aims to accelerate CMC registrational readiness for therapies with expedited clinical development timelines [1].

Moreover, Lexeo announced the closing of an $80 million equity financing round, which will support the development of its clinical stage pipeline. The company expects this funding to provide operational runway into 2028 [1]. Additionally, Lexeo has formed a strategic partnership with Perceptive Xontogeny Venture Funds and venBio Partners to advance non-viral, RNA-based therapeutics for genetic cardiac diseases [1].

The company's financial results for the second quarter of 2025 showed a cash position of $152.5 million, which is expected to be sufficient to fund operations into 2028. Research and Development expenses were $14.7 million for the period, while General and Administrative expenses were $16.0 million [1].

The appointment of Louis Tamayo as Chief Financial Officer further strengthens Lexeo's leadership. Mr. Tamayo brings extensive commercial finance experience and will support the company's late-stage clinical and commercialization plans [1].

Despite the positive developments, investors should remain cautious due to the inherent risks associated with clinical trials and the regulatory approval process. Lexeo's forward-looking statements highlight potential risks and uncertainties, including global macroeconomic conditions and the progress of its preclinical studies [1].

References:
[1] https://www.globenewswire.com/news-release/2025/08/14/3133352/0/en/Lexeo-Therapeutics-Reports-Second-Quarter-2025-Financial-Results-and-Operational-Highlights.html